Therapeutic haemoglobin synthesis in β-thalassaemic mice expressing lentivirus-encoded human β-globin
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The stable introduction of a functional beta-globin gene in haematopoietic stem cells could be a powerful approach to treat beta-thalassaemia and sickle-cell disease. Genetic approaches aiming to increase normal beta-globin expression in the progeny of autologous haematopoietic stem cells might circumvent the limitations and risks of allogeneic cell transplants. However, low-level expression, position effects and transcriptional silencing hampered the effectiveness of viral transduction of the human beta-globin gene when it was linked to minimal regulatory sequences. Here we show that the use of recombinant lentiviruses enables efficient transfer and faithful integration of the human beta-globin gene together with large segments of its locus control region. In long-term recipients of unselected transduced bone marrow cells, tetramers of two murine alpha-globin and two human betaA-globin molecules account for up to 13% of total haemoglobin in mature red cells of normal mice. In beta-thalassaemic heterozygous mice higher percentages are obtained (17% to 24%), which are sufficient to ameliorate anaemia and red cell morphology. Such levels should be of therapeutic benefit in patients with severe defects in haemoglobin production.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After establishing that β-globin lentiviral vectors had successfully corrected models of β-thalassemia and sickle cell disease in mice, 17,18 we initiated a human clinical study of ex vivo gene therapy for the β-hemoglobinopathies”
From Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia (2018) · cites this paper as [17]
Citations
Cites
A Third-Generation Lentivirus Vector with a Conditional Packaging System
Dull, T., Zufferey, R., Kelly, M., Mandel, R. J., Nguyen, M., Trono, D., & Naldini, L. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8463-8471.1998 · Cited by 3,341
Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo
Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., & Trono, D. (1997) · Nature Biotechnology · doi:10.1038/nbt0997-871 · Cited by 1,977
Position-independent, high-level expression of the human β-globin gene in transgenic mice
Grosveld, F., van Assendelft, G. B., Greaves, D. R., & Kollias, G. (1987) · Cell · doi:10.1016/0092-8674(87)90584-8 · Cited by 1,909 · cited 1×
“, referred to as the locus control region (LCR), are linked to the globin gen”
BackgroundMalim, M. H., Hauber, J., Le, S.-Y., Maizel, J. V., & Cullen, B. R. (1989) · Nature · doi:10.1038/338254a0 · Cited by 1,280 · cited 1×
“Here we report how these problems may be overcome by using vectors derived from human immunodeficiency virus 1, a retrovirus that has the ability to regulate packaging of unspliced viral genome”
Hematology of Infancy and Childhood.
(1975) · Annals of Internal Medicine · doi:10.7326/0003-4819-83-4-587_2 · Cited by 892
The Molecular Basis of Blood Diseases.
(1987) · Annals of Internal Medicine · doi:10.7326/0003-4819-107-6-950_3 · Cited by 632
Miyoshi, H., Smith, K. A., Mosier, D. E., Verma, I. M., & Torbett, B. E. (1999) · Science · doi:10.1126/science.283.5402.682 · Cited by 624
The "beta-like-globin" gene domain in human erythroid cells.
Tuan, D., Solomon, W., Li, Q., & London, I. M. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.19.6384 · Cited by 601 · cited 1×
“The same outcome prevails in transgenic mice unless genomic elements encompassing DNase I hypersensitive sites (HS) located 60 kilobases (kb) upstream of the human β-globin gen”
BackgroundLooping versus linking: toward a model for long-distance gene activation
Bulger, M., & Groudine, M. (1999) · Genes & Development · doi:10.1101/gad.13.19.2465 · Cited by 484
Raj, S. R., Chen, S. R. W., Sheldon, R. S., Shah, A. N., Kantharia, B. K., Salzer, U., Grimbacher, B., Leung, A. K. C., Kamat, D., Kolovou, G. D., et al. (2009) · Encyclopedia of Molecular Mechanisms of Disease · doi:10.1007/978-3-540-29676-8_1731 · Cited by 475
Cited by
Dunbar, C. E., High, K. A., Joung, J. K., Kohn, D. B., Ozawa, K., & Sadelain, M. (2018) · Science · doi:10.1126/science.aan4672 · Cited by 1,410
Self-citationViral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics
Kay, M. A., Glorioso, J. C., & Naldini, L. (2001) · Nature Medicine · doi:10.1038/83324 · Cited by 1,342
“The potential of this new approach to improve gene transfer into HSC was dramatically shown in a recent report describing therapeutic correction of a mouse model of β-thalassaemi”
BackgroundTransfusion independence and HMGA2 activation after gene therapy of human β-thalassaemia
Cavazzana-Calvo, M., Payen, E., Negre, O., Wang, G., Hehir, K., Fusil, F., Down, J., Denaro, M., Brady, T., Westerman, K., et al. (2010) · Nature · doi:10.1038/nature09328 · Cited by 1,276
“Numbers along the top indicate blood progenitors from a b-thalassaemic control individual (1), patient P2’s blood progenitors 27 months posttransplantation showing a band consistent with truncated fusion protein of 135 amino acids (2), recombinant truncated (73 amino acids) (4) and fulllength (109 amino acids) (5) hum…”
BackgroundRund, D., & Rachmilewitz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050436 · Cited by 939
In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers
Smith, T. T., Stephan, S. B., Moffett, H. F., McKnight, L. E., Ji, W., Reiman, D., Bonagofski, E., Wohlfahrt, M. E., Pillai, S. P. S., & Stephan, M. T. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.57 · Cited by 785
Guidelines for the Management of Transfusion Dependent Thalassaemia (TDT)
Cappellini, M. D., Cohen, A. R., Porter, J. B., Taher, A. T., & Viprakasit, V. (2014) · Cited by 726
Gene Therapy in Patients with Transfusion-Dependent β-Thalassemia
Thompson, A. A., Walters, M. C., Kwiatkowski, J., Rasko, J. E. J., Ribeil, J.-A., Hongeng, S., Magrin, E., Schiller, G. J., Payen, E., Semeraro, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1705342 · Cited by 684
Correction of sickle cell disease in transgenic mouse models by gene therapy
Pawliuk, R., Westerman, K. A., Fabry, M. E., Payen, E., Tighe, R., Bouhassira, E. E., Acharya, S. A., Ellis, J., London, I. M., Eaves, C. J., et al. (2001) · Science · doi:10.1126/science.1065806 · Cited by 579
Gene therapy: trials and tribulations
Somia, N., & Verma, I. M. (2000) · Nature Reviews Genetics · doi:10.1038/35038533 · Cited by 554
“gov/htbin-post/Omim/dispmim?187550"> β-thalassaemia”
Systematic Determination of the Packaging Limit of Lentiviral Vectors
Kumar, M., Keller, B., Makalou, N., & Sutton, R. E. (2001) · Human Gene Therapy · doi:10.1089/104303401753153947 · Cited by 454
“V – ) varied between 1–4 3 10 6 IU/ml. ( onstrated for b -globin (May et al., 2000).”
Side effects of retroviral gene transfer into hematopoietic stem cells
Baum, C., Düllmann, J., Li, Z., Fehse, B., Meyer, J., Williams, D. A., & von Kalle, C. (2003) · Blood · doi:10.1182/blood-2002-07-2314 · Cited by 435
Higgs, D. R., Engel, J. D., & Stamatoyannopoulos, G. (2012) · The Lancet · doi:10.1016/s0140-6736(11)60283-3 · Cited by 434
Rachmilewitz, E. A., & Giardina, P. J. (2011) · Blood · doi:10.1182/blood-2010-08-300335 · Cited by 417
Silencing and Variegation of Gammaretrovirus and Lentivirus Vectors
Ellis, J. (2005) · Human Gene Therapy · doi:10.1089/hum.2005.16.1241 · Cited by 379
Mutagenesis and Oncogenesis by Chromosomal Insertion of Gene Transfer Vectors
Baum, C., Kustikova, O., Modlich, U., Li, Z., & Fehse, B. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.253 · Cited by 360
Ex vivo gene transfer and correction for cell-based therapies
Naldini, L. (2011) · Nature Reviews Genetics · doi:10.1038/nrg2985 · Cited by 358
“In addition, certain applications strictly require switching on expression — and reaching very high expression levels — at only the proper stage of differentiation, such as in the case of globin transgenes used for HSC gene therapy of β-thalassaemi”
BackgroundGene delivery by lentivirus vectors
Cockrell, A. S., & Kafri, T. (2007) · Molecular Biotechnology · doi:10.1007/s12033-007-0010-8 · Cited by 355
Recent Advances in Lentiviral Vector Development and Applications
Mátrai, J., Chuah, M. K., & VandenDriessche, T. (2010) · Molecular Therapy · doi:10.1038/mt.2009.319 · Cited by 347
Occurrence of leukaemia following gene therapy of X-linked SCID
Kohn, D. B., Sadelain, M., & Glorioso, J. C. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1122 · Cited by 344
“These vectors, which are designed to express the β-chain of haemoglobin specifically in maturing proerythroblasts, require that many transcriptional control elements and chromatin-structure determinants be optimally combine”
BackgroundSelf-citationGene Therapy: Promises and Problems
Pfeifer, A., & Verma, I. M. (2001) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev.genom.2.1.177 · Cited by 340
Lentiviral vectors: basic to translational
Sakuma, T., Barry, M. A., & Ikeda, Y. (2012) · Biochemical Journal · doi:10.1042/bj20120146 · Cited by 336
Gujja, P., Rosing, D. R., Tripodi, D. J., & Shizukuda, Y. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.083 · Cited by 327
Papapetrou, E. P., Lee, G., Malani, N., Setty, M., Riviere, I., Tirunagari, L. M. S., Kadota, K., Roth, S. L., Giardina, P., Viale, A., et al. (2011) · Nature Biotechnology · doi:10.1038/nbt.1717 · Cited by 299
“We investigated this approach in an iPS cell model for the genetic correction of β-thalassemia major using a well-characterized globin lentiviral vecto”
MethodSelf-citationAnemia: progress in molecular mechanisms and therapies
Sankaran, V. G., & Weiss, M. J. (2015) · Nature Medicine · doi:10.1038/nm.3814 · Cited by 281
Immunotherapy through TCR gene transfer
Kessels, H. W. H. G., Wolkers, M. C., van den Boom, M. D., van den Valk, M. A., & Schumacher, T. N. M. (2001) · Nature Immunology · doi:10.1038/ni1001-957 · Cited by 279
“Although for many applications of redirected T cells long-term T cell memory may not be required, it will be useful to establish the effects of TCR transfer with improved viral delivery systems that are less sensitive to transcriptional silencin”
BackgroundGene Therapy with Viral Vectors
Kootstra, N. A., & Verma, I. M. (2003) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.43.100901.140257 · Cited by 267
Hematopoietic Stem Cell Gene Therapy: Progress and Lessons Learned
Morgan, R. A., Gray, D., Lomova, A., & Kohn, D. B. (2017) · Cell Stem Cell · doi:10.1016/j.stem.2017.10.010 · Cited by 245
“In some cases, it has been possible to build vectors using transcriptional control elements from endogenous cellular genes to apply regulated expression of transgenes (e.g., beta-globin transcriptional control elements directing erythroid-specific expression of beta-globin; May et al., 2000).”
BackgroundFollenzi, A., Sabatino, G., Lombardo, A., Boccaccio, C., & Naldini, L. (2002) · Human Gene Therapy · doi:10.1089/10430340252769770 · Cited by 244
Rivella, S., May, C., Chadburn, A., Rivière, I., & Sadelain, M. (2003) · Blood · doi:10.1182/blood-2002-10-3305 · Cited by 220
Self-citationHanawa, H., Kelly, P. F., Nathwani, A. C., Persons, D. A., Vandergriff, J. A., Hargrove, P., Vanin, E. F., & Nienhuis, A. W. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0549 · Cited by 205
“Also, lentiviral vectors seem superior at transferring complex vector genomes with multiple regulatory elements necessary to achieve high-level, tissue-specific expression [18,40].”
BackgroundObesity genetics in mouse and human: back and forth, and back again
Yazdi, F. T., Clee, S. M., & Meyre, D. (2015) · PeerJ · doi:10.7717/peerj.856 · Cited by 196
Levasseur, D. N., Ryan, T. M., Pawlik, K. M., & Townes, T. M. (2003) · Blood · doi:10.1182/blood-2003-04-1251 · Cited by 195
Genetic treatment of a molecular disorder: gene therapy approaches to sickle cell disease
Hoban, M. D., Orkin, S. H., & Bauer, D. E. (2016) · Blood · doi:10.1182/blood-2015-09-618587 · Cited by 194
Tabar, V., Panagiotakos, G., Greenberg, E. D., Chan, B. K., Sadelain, M., Gutin, P. H., & Studer, L. (2005) · Nature Biotechnology · doi:10.1038/nbt1088 · Cited by 194
“Vectors were produced by triple transfection of human embryonic kidney 293 cells followed by ultracentrifugation and titration as previously describe”
MethodSelf-citationImren, S., Payen, E., Westerman, K. A., Pawliuk, R., Fabry, M. E., Eaves, C. J., Cavilla, B., Wadsworth, L. D., Beuzard, Y., Bouhassira, E. E., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.212507099 · Cited by 188
Successful correction of the human β-thalassemia major phenotype using a lentiviral vector
Puthenveetil, G., Scholes, J., Carbonell, D., Qureshi, N., Xia, P., Zeng, L., Li, S., Yu, Y., Hiti, A. L., Yee, J.-K., et al. (2004) · Blood · doi:10.1182/blood-2004-04-1427 · Cited by 182
Cappellini, M. D., Porter, J. B., Viprakasit, V., & Taher, A. T. (2018) · Blood Reviews · doi:10.1016/j.blre.2018.02.001 · Cited by 182
Silencing of gene expression: implications for design of retrovirus vectors
Pannell, D., & Ellis, J. (2001) · Reviews in Medical Virology · doi:10.1002/rmv.316 · Cited by 174
Biosafety Features of Lentiviral Vectors
Schambach, A., Zychlinski, D., Ehrnstroem, B., & Baum, C. (2013) · Human Gene Therapy · doi:10.1089/hum.2012.229 · Cited by 173
“The most prominent example for this is the successful transduction of complex globin expression cassettes, which contain larger pieces of regulatory DNA and introns (May et al., 2000; Pawliuk et al., 2001; Roselli et al., 2010).”
Promoters and Control Elements: Designing Expression Cassettes for Gene Therapy
Papadakis, E., Nicklin, S., Baker, A., & White, S. (2004) · Current Gene Therapy · doi:10.2174/1566523044578077 · Cited by 170
A Phase I/II Clinical Trial of β‐Globin Gene Therapy for β‐Thalassemia
BANK, A., DORAZIO, R., & LEBOULCH, P. (2005) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1345.007 · Cited by 169
Lentiviral vectors: optimization of packaging, transduction and gene expression
Delenda, C. (2004) · The Journal of Gene Medicine · doi:10.1002/jgm.501 · Cited by 132
Allogeneic hematopoietic stem cell transplantation for sickle cell disease: the time is now
Hsieh, M. M., Fitzhugh, C. D., & Tisdale, J. F. (2011) · Blood · doi:10.1182/blood-2011-01-332510 · Cited by 152
Miccio, A., Cesari, R., Lotti, F., Rossi, C., Sanvito, F., Ponzoni, M., Routledge, S. J. E., Chow, C.-M., Antoniou, M. N., & Ferrari, G. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0711666105 · Cited by 154
Gene therapy for sickle cell disease: An update
Demirci, S., Uchida, N., & Tisdale, J. F. (2018) · Cytotherapy · doi:10.1016/j.jcyt.2018.04.003 · Cited by 165
Successful treatment of murine β-thalassemia intermedia by transfer of the human β-globin gene
May, C., Rivella, S., Chadburn, A., & Sadelain, M. (2002) · Blood · doi:10.1182/blood.v99.6.1902 · Cited by 164
Self-citationJedinak, A., Dudhgaonkar, S. P., Wu, Q., Simon, J., & Slíva, D. (2011) · Nutrition Journal · doi:10.1186/1475-2891-10-52 · Cited by 164
Erythropoiesis: insights into pathophysiology and treatments in 2017
Zivot, A., Lipton, J. M., Narla, A., & Blanc, L. (2018) · Molecular Medicine · doi:10.1186/s10020-018-0011-z · Cited by 163
Advances in the allogeneic transplantation for thalassemia
Lucarelli, G., & Gaziev, J. (2008) · Blood Reviews · doi:10.1016/j.blre.2007.10.001 · Cited by 162
Ramezani, A., Hawley, T. S., & Hawley, R. G. (2003) · Blood · doi:10.1182/blood-2002-09-2991 · Cited by 144
Persons, D. A., Hargrove, P. W., Allay, E. R., Hanawa, H., & Nienhuis, A. W. (2003) · Blood · doi:10.1182/blood-2002-07-2211 · Cited by 155
Gene Therapy of the β-Hemoglobinopathies by Lentiviral Transfer of the β A(T87Q) - Globin Gene
Negre, O., Eggimann, A.-V., Beuzard, Y., Ribeil, J.-A., Bourget, P., Borwornpinyo, S., Hongeng, S., Hacein-Bey, S., Cavazzana, M., Leboulch, P., et al. (2016) · Human Gene Therapy · doi:10.1089/hum.2016.007 · Cited by 159
Hanawa, H., Hematti, P., Keyvanfar, K., Metzger, M. E., Krouse, A., Donahue, R. E., Kepes, S., Gray, J., Dunbar, C. E., Persons, D. A., et al. (2004) · Blood · doi:10.1182/blood-2004-01-0045 · Cited by 159
HIV-Based Vectors: Preparation and Use
Follenzi, A., & Naldini, L. (2003) · Gene Therapy Protocols · doi:10.1385/1-59259-141-8:259 · Cited by 143
The human β‐globin locus control region: A center of attraction
Levings, P. P., & Bungert, J. (2002) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2002.02797.x · Cited by 144
Imren, S., Fabry, M. E., Westerman, K. A., Pawliuk, R., Tang, P., Rosten, P. M., Nagel, R. L., Leboulch, P., Eaves, C. J., & Humphries, R. K. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200421838 · Cited by 126
Arumugam, P. I., Scholes, J., Perelman, N., Xia, P., Yee, J.-K., & Malik, P. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300259 · Cited by 124
Lentiviral vectors, two decades later
Naldini, L., Trono, D., & Verma, I. M. (2016) · Science · doi:10.1126/science.aah6192 · Cited by 123
Lignin Nanotubes As Vehicles for Gene Delivery into Human Cells
Ten, E., Ling, C., Wang, Y., Srivastava, A., Dempere, L. A., & Vermerris, W. (2013) · Biomacromolecules · doi:10.1021/bm401555p · Cited by 132
Persons, D. A., Allay, E. R., Sawai, N., Hargrove, P. W., Brent, T. P., Hanawa, H., Nienhuis, A. W., & Sorrentino, B. P. (2003) · Blood · doi:10.1182/blood-2003-03-0677 · Cited by 130
Pathophysiology and therapy for haemoglobinopathies; Part I: sickle cell disease
Madigan, C., & Malik, P. (2006) · Expert Reviews in Molecular Medicine · doi:10.1017/s1462399406010659 · Cited by 106
β-globin gene transfer to human bone marrow for sickle cell disease
Romero, Z., Urbinati, F., Geiger, S., Cooper, A. R., Wherley, J., Kaufman, M. L., Hollis, R. P., Ruiz de Assin, R., Senadheera, S., Sahagian, A., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67930 · Cited by 107
“vectors are reduced compared with those of vectors bearing simpler cassettes (17, 18).”
Scalable Lentiviral Vector Production Using Stable HEK293SF Producer Cell Lines
Manceur, A. P., Kim, H. S., Misic, V., Andreev, N., Dorion-Thibaudeau, J., Lanthier, S., Bernier, A., Tremblay, S., Gélinas, A.-M., Broussau, S., et al. (2017) · Human Gene Therapy Methods · doi:10.1089/hgtb.2017.086 · Cited by 124
Harnessing HIV for therapy, basic research and biotechnology
Wiznerowicz, M., & Trono, D. (2004) · Trends in biotechnology · doi:10.1016/j.tibtech.2004.11.001 · Cited by 124
Retrovirus Vectors: Toward the Plentivirus?
Baum, C., Schambach, A., Bohne, J., & Galla, M. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.03.007 · Cited by 104
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors
Zakrzewski, J. L., Suh, D. Y., Markley, J. C., Smith, O. M., King, C. G., Goldberg, G. L., Jenq, R. R., Holland, A. M., Grubin, J., Cabrera-Pérez, J., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt1395 · Cited by 124
Self-citationHanawa, H., Hargrove, P. W., Kepes, S., Srivastava, D. K., Nienhuis, A. W., & Persons, D. A. (2004) · Blood · doi:10.1182/blood-2004-03-0863 · Cited by 115
Emery, D. W., Yannaki, E., Tubb, J., Nishino, T., Li, Q., & Stamatoyannopoulos, G. (2002) · Blood · doi:10.1182/blood-2002-01-0219 · Cited by 116
Moreau-Gaudry, F., Xia, P., Jiang, G., Perelman, N. P., Bauer, G., Ellis, J., Surinya, K. H., Mavilio, F., Shen, C.-K., & Malik, P. (2001) · Blood · doi:10.1182/blood.v98.9.2664 · Cited by 115
Samakoglu, S., Lisowski, L., Budak-Alpdoǧan, T., Usachenko, Y., Acuto, S., Marzo, R. D., Maggio, A., Zhu, P., Tisdale, J. F., Rivière, I., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1176 · Cited by 122
“MEL cells were transduced at low multiplicity of infection with the G9 or CPD vectors, selected in MTX, and differentiated to induce endogenous globin expressio”
Self-citationEmerging genetic therapy for sickle cell disease
Orkin, S. H., & Bauer, D. E. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-041817-125507 · Cited by 119
Zhou, S., Mody, D., DeRavin, S. S., Hauer, J., Lu, T., Ma, Z., Hacein-Bey Abina, S., Gray, J. T., Greene, M. R., Cavazzana-Calvo, M., et al. (2010) · Blood · doi:10.1182/blood-2009-10-250209 · Cited by 119
Hargrove, P. W., Kepes, S., Hanawa, H., Obenauer, J. C., Pei, D., Cheng, C., Gray, J. T., Neale, G., & Persons, D. A. (2008) · Molecular Therapy · doi:10.1038/sj.mt.6300394 · Cited by 110
Current and future alternative therapies for beta-thalassemia major
Dreuzy, E. D., Bhukhai, K., Leboulch, P., & Payen, E. (2016) · Biomedical Journal · doi:10.1016/j.bj.2015.10.001 · Cited by 115
Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies
Magrin, E., Miccio, A., & Cavazzana, M. (2019) · Blood · doi:10.1182/blood.2019000949 · Cited by 114
Gene therapy of inherited diseases
Fischer, A., & Cavazzana, M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60874-0 · Cited by 112
Wu, B., Miskolci, V., Sato, H., Tutucci, E., Kenworthy, C. A., Donnelly, S. K., Yoon, Y. J., Cox, D., Singer, R. H., & Hodgson, L. (2015) · Genes & Development · doi:10.1101/gad.259358.115 · Cited by 102
“As the retroviral transductions can target with great efficiency both dividing and nondividing cells, including stem cells and neurons (Naldini et al. 1996; May et al. 2000), both in vitro and in vivo, it is critical to side-step this random deletion problem.”
Emery, D. W. (2011) · Human Gene Therapy · doi:10.1089/hum.2010.233 · Cited by 92
“…can also be overcome in part through the judicious use of enhancers and promoters (Ellis, 2005), as well as other regulatory elements that modulate chromatin structure, such as locus control regions (May et al. , 2000), scaffold attachment regions (Ramezani et al. , 2003), or autonomous chromatin”
Advances in lentiviral vector design for gene-modification of hematopoietic stem cells
Logan, A. C., Lutzko, C., & Kohn, D. B. (2002) · Current Opinion in Biotechnology · doi:10.1016/s0958-1669(02)00346-4 · Cited by 110
Pestina, T. I., Hargrove, P. W., Jay, D., Gray, J. T., Boyd, K. M., & Persons, D. A. (2009) · Molecular Therapy · doi:10.1038/mt.2008.259 · Cited by 104
Carrier strategies boost the application of CRISPR/Cas system in gene therapy
Xu, Z., Wang, Q., Zhong, H., Jiang, Y., Shi, X., Yuan, B., Yu, N., Zhang, S., Yuan, X., Guo, S., et al. (2022) · Exploration · doi:10.1002/exp.20210081 · Cited by 109
Chapin, J. C., & Giardina, P. J. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00040-8 · Cited by 108
Wilber, A., Hargrove, P. W., Kim, Y.-S., Riberdy, J. M., Sankaran, V. G., Papanikolaou, E., Georgomanoli, M., Anagnou, N. P., Orkin, S. H., Nienhuis, A. W., et al. (2011) · Blood · doi:10.1182/blood-2010-08-300723 · Cited by 99
Gene therapy of severe combined immunodeficiencies
Fischer, A., Hacein‐Bey‐Abina, S., & Cavazzana, M. (2002) · Nature reviews. Immunology · doi:10.1038/nri859 · Cited by 107
“Combined with the use of restricted lineage expression, as shown for haemoglobin expression in erythroid cell”
MethodRecent trends in the gene therapy of β-thalassemia
Gambari, R., Finotti, A., Breda, L., Lederer, C. W., Bianchi, N., Zuccato, C., Klenathous, M., & Rivella, S. (2015) · Journal of Blood Medicine · doi:10.2147/jbm.s46256 · Cited by 106
Self-citationGene transfer into murine hematopoietic stem cells with helper-free foamy virus vectors
Vassilopoulos, G., Trobridge, G. D., Josephson, N. C., & Russell, D. W. (2001) · Blood · doi:10.1182/blood.v98.3.604 · Cited by 102
Genetically targeted radiotherapy for multiple myeloma
Dingli, D., Díaz, R. M., Bergert, E. R., O’Connor, M. K., Morris, J. C., & Russell, S. J. (2003) · Blood · doi:10.1182/blood-2002-11-3390 · Cited by 101
Two decades of clinical gene therapy--success is finally mounting.
Herzog, R. W., Cao, O., & Srivastava, A. (2010) · PubMed · Cited by 100
Ailles, L., Schmidt, M., Santoni de Sio, F. R., Glimm, H., Cavalieri, S., Bruno, S., Piacibello, W., Von Kalle, C., & Naldini, L. (2002) · Molecular Therapy · doi:10.1006/mthe.2002.0720 · Cited by 95
Chang, A. H., & Sadelain, M. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300060 · Cited by 88
Self-citationPersons, D. A., Allay, E. R., Sabatino, D. E., Kelly, P. F., Bodine, D. M., & Nienhuis, A. W. (2001) · Blood · doi:10.1182/blood.v97.10.3275 · Cited by 97
Aker, M., Tubb, J., Groth, A. C., Bukovsky, A. A., Bell, A. C., Felsenfeld, G., Kiem, H.-P., Stamatoyannopoulos, G., & Emery, D. W. (2007) · Human Gene Therapy · doi:10.1089/hum.2007.021 · Cited by 92
Hamaguchi, I., Ooka, A., Brun, A. C. M., Richter, J., Dahl, N., & Karlsson, S. (2002) · Blood · doi:10.1182/blood.v100.8.2724 · Cited by 96
Tisdale, J. F., Thein, S. L., & Eaton, W. A. (2020) · Science · doi:10.1126/science.aba3827 · Cited by 95
Exploring Strategies for the Design of Artificial Transcription Factors
Gräslund, T., Li, X., Magnenat, L., Popkov, M., & Barbas, C. F. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m406809200 · Cited by 82
Prospects and implications of using chromatin insulators in gene therapy and transgenesis
Recillas‐Targa, F., Valadez‐Graham, V., & Farrell, C. M. (2004) · BioEssays · doi:10.1002/bies.20059 · Cited by 79
Chen, J., Yang, W., Li, G., Qian, J., Xue, J., Fu, S., & Lu, D. (2004) · World Journal of Gastroenterology · doi:10.3748/wjg.v10.i1.112 · Cited by 90
A new frontier: FDA approvals for gene therapy in sickle cell disease
Leonard, A. K., & Tisdale, J. F. (2024) · Molecular Therapy · doi:10.1016/j.ymthe.2024.01.015 · Cited by 90
HIV-1-Derived Lentiviral Vectors
Ailles, L., & Naldini, L. (2002) · Current topics in microbiology and immunology · doi:10.1007/978-3-642-56114-6_2 · Cited by 89
Molecular therapies in β‐thalassaemia
Quek, L., & Thein, S. L. (2007) · British Journal of Haematology · doi:10.1111/j.1365-2141.2006.06408.x · Cited by 88
“Transfected b-thalassaemia intermedia mice showed sustained rises in haemoglobin of around 38 g/l (May et al, 2000).”
BackgroundResult
Metadata
- Authors
- May, C., Rivella, S., Callegari, J., Heller, G., Gaensler, K. M. L., Luzzatto, L., & Sadelain, M.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- University of California, San Francisco (US)
- Corresponding author
- Sadelain, Michel
- Venue
- Nature
- Published
- 2000-07
- Volume
- 406
- Issue
- 6791
- Pages
- 82-86
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1997170085
- Cited by
- 567
- References
- 34
- Citations by year
- 2026: 3 · 2025: 8 · 2024: 6 · 2023: 11 · 2022: 11 · 2021: 10 · 2020: 10 · 2019: 16 · 2018: 26 · 2017: 18 · 2016: 16 · 2015: 15 · 2014: 13 · 2013: 22 · 2012: 24
- FWCI
- 24.68
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- James S. McDonnell Foundation
- National Heart, Lung, and Blood Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Genetics (clinical) › Hemoglobinopathies and Related Disorders
- Health Sciences › Medicine › Hematology › Hematopoietic Stem Cell Transplantation
- Keywords
- beta-thalassemia, sickle cell disease, lentiviral transduction, human beta-globin gene, hematopoietic stem cells, locus control region, hemoglobin synthesis, anemia, erythrocyte morphology, position effect, transcriptional silencing
- MeSH terms
- Animals, Cell Line, Female, Genetic Vectors, Globins, Hemoglobins, Humans, Male, Recombinant Proteins, Transduction, Genetic, Genetic Therapy, HIV-1, Bone Marrow Transplantation, Lentivirus, beta-Thalassemia, Gene Transfer Techniques, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.